Hemogenyx Pharmaceuticals Interim Earnings Report

Hemogenyx Pharmaceuticals EPS Results

• Actual EPS: -GBX 0.83
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Hemogenyx Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Hemogenyx Pharmaceuticals Announcement Details

• Quarter: Interim
• Date: 9/30/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Hemogenyx Pharmaceuticals (LON:HEMO), a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.